Recent Quotes (30 days)

You have no recent quotes
chg | %

Welichem Biotech Inc.  

(Public, CVE:WBI)   Watch this stock  
Find more results for WBI
-0.105 (-31.82%)
Apr 22 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.22 - 0.22
52 week 0.10 - 0.75
Open 0.22
Vol / Avg. 2,000.00/773.00
Mkt cap 13.38M
P/E     -
Div/yield     -
EPS -0.12
Shares 59.46M
Beta -3.47
Inst. own     -

Key stats and ratios

Q3 (Aug '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -1.32% 217.48%
Return on average equity -1.32% 263.43%
CDP Score - -


316-4475 Wayburne Drive
+1-604-4321703 (Phone)
+1-604-4321704 (Fax)

Website links


Welichem Biotech Inc. is a drug discovery and early-stage drug development company. The Company focuses on new therapeutics for autoimmune/inflammatory diseases and cancers. The Company is dedicated to research and development of its anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. All the Company´┐Żs drug candidates are derived from the metabolites of bacterial symbionts of soil living nematodes. Using its Symbiochem technology platform, the Company has developed a robust pipeline of compounds that target various diseases, including inflammatory diseases and cancers. WBI-1001 targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. On July 31, 2012, the WBI-1001 technology was acquired by Stiefel, a Glaxo Group Limited (GSK) company.

Officers and directors

Liren Tang President, Chief Executive Officer
Harvey S. K. Quan Chief Financial Officer, Secretary
M Lyle Vice President - Research & Development
Ryan B. Zeng Director
J Dai Independent Director
Guoqing Li Independent Director
Lai Lv Independent Director